{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/scabies/prescribing-information/crotamiton-10percent-cream/","result":{"pageContext":{"chapter":{"id":"384c43f2-9128-5f2d-92dd-f064f115544a","slug":"crotamiton-10percent-cream","fullItemName":"Crotamiton 10% cream","depth":2,"htmlHeader":"<!-- begin field 34c49a95-13e1-4973-bf6c-a83d0000f9c3 --><h2>Crotamiton 10% cream</h2><!-- end field 34c49a95-13e1-4973-bf6c-a83d0000f9c3 -->","summary":"","htmlStringContent":"<!-- begin item 4fc42b18-4890-4146-b0e9-a83d0000f2ed --><!-- end item 4fc42b18-4890-4146-b0e9-a83d0000f2ed -->","topic":{"id":"2239c8be-00a0-56aa-8fe9-0467b238f0c4","topicId":"da2824e2-e1de-4303-9c52-8224034ff953","topicName":"Scabies","slug":"scabies","lastRevised":"Last revised in November 2017","chapters":[{"id":"da8e838e-f347-56db-afd1-75fbd32ad909","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8230d8c6-45b3-5bdb-8cc8-3c1c2b823449","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a4632036-ac3e-5da5-9aff-ee789e83a368","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f3a44b9a-af69-5c7d-9a47-6dc02fafa709","slug":"changes","fullItemName":"Changes"},{"id":"4d9cd925-2e05-5383-933f-f483f2ed7fdc","slug":"update","fullItemName":"Update"}]},{"id":"a65309c1-f446-573c-a812-cd9a67f28cc7","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a68dada3-3034-53ad-9477-23904345690e","slug":"goals","fullItemName":"Goals"},{"id":"bbbd25ab-ead3-5868-b558-5283d76c73ea","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c05af2ff-93bf-5065-acf0-511a278d4cdf","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b592bb65-acf3-54c5-9e50-f1d986ef2099","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6fdf1f82-f5bd-5ebe-b440-d5e2b673f214","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7c704acb-f3b9-5169-b8e6-a401a805fb9f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e967b469-438f-5a3c-b576-bb55b8cd46c0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5119a491-fd63-525d-9787-b77adf1ad31a","slug":"definition","fullItemName":"Definition"},{"id":"d4abdef1-d529-5524-a289-d515c8900234","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8bc35f21-913e-5a50-b011-2b928b93c033","slug":"transmission","fullItemName":"Transmission"},{"id":"1a3cadf7-aa8c-5437-9b8c-ebf6a885e18d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"2065f768-9383-5d5e-8dd5-a0411d51dade","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"783dffe4-5b71-5b67-8b76-aa6d05b04591","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9fde1af7-a79f-56cf-b595-ac0691f21b5f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"177fab9d-042e-5ed5-bef2-4b96c7157717","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"a4fb57b7-6e89-5bc6-8768-5a2a59312f92","slug":"basis-for-recommendation-501","fullItemName":"Basis for recommendation"}]},{"id":"f0095d1b-7de8-51f8-86f9-51236504dc2c","fullItemName":"Management","slug":"management","subChapters":[{"id":"b8090f99-a407-59d0-bd90-cad808bf8bbf","slug":"management-of-scabies","fullItemName":"Scenario: Management of scabies"}]},{"id":"a3c66bd0-4e63-5096-98e7-3648f3a19fa5","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"82606908-d488-536f-badf-4311c083f9f2","slug":"insecticides","fullItemName":"Insecticides"},{"id":"e0ff263e-9d39-5b6e-a192-b3c23f35b8e2","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"87495d38-99d2-59af-ab1b-3701df31a332","slug":"chlorphenamine-hydroxyzine","fullItemName":"Chlorphenamine and hydroxyzine:"},{"id":"384c43f2-9128-5f2d-92dd-f064f115544a","slug":"crotamiton-10percent-cream","fullItemName":"Crotamiton 10% cream"}]},{"id":"d23e8a1b-527a-5b4e-bc6e-1550c1d7b7f7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bf5d0fd9-3845-54be-8307-14fee2b8fe46","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"24a603a9-c1be-5619-9cab-6e8cc775ec79","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"862928da-a3ad-5b3c-b1fa-c221c79d2e0a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c1f2f20f-1192-5385-b710-2f4aeb402bc9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"42e0b79b-5cd7-53cd-bc72-422e96a7aaf4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"324db100-c4d0-5d57-9a1f-c8487c474f9e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"860692e0-5ebd-5bb6-8862-8c22738325ca","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a3c66bd0-4e63-5096-98e7-3648f3a19fa5","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"2ae8d8a9-cb57-5767-8c87-8d3a14de0c08","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field cac62807-8953-4b47-a705-a83d0001b2c9 --><h3>Contraindications and cautions</h3><!-- end field cac62807-8953-4b47-a705-a83d0001b2c9 -->","summary":"","htmlStringContent":"<!-- begin item 6fc72720-3c4b-4e32-8f44-a83d0001adb3 --><!-- begin field 000e6364-7b8f-4c42-ba2e-a83d0001b2c9 --><p>Do not prescribe crotamiton to people with acute exudative dermatoses.</p><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI Medicines Compendium, 2007</a>] </p><!-- end field 000e6364-7b8f-4c42-ba2e-a83d0001b2c9 --><!-- end item 6fc72720-3c4b-4e32-8f44-a83d0001adb3 -->","subChapters":[]},{"id":"7f153560-36fe-5966-a11e-fd793051c9d1","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3e311a56-9bc2-4ede-8b60-a83d0002317b --><h3>Adverse effects</h3><!-- end field 3e311a56-9bc2-4ede-8b60-a83d0002317b -->","summary":"","htmlStringContent":"<!-- begin item 5c523025-de82-4634-91bc-a83d00022db1 --><!-- begin field afbd5924-d928-4fbb-9d22-a83d0002317b --><p>Adverse effects of crotamiton cream include pruritis, contact dermatitis, and hypersensitivity (such as rash, eczema, erythema, skin irritation, angioedema).</p><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2017b</a>] </p><!-- end field afbd5924-d928-4fbb-9d22-a83d0002317b --><!-- end item 5c523025-de82-4634-91bc-a83d00022db1 -->","subChapters":[]},{"id":"2eeeb156-8175-5bbe-be67-dd37e5f5b46a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 55a71729-db51-49ef-b09d-a83f00fdfdf4 --><h3>Drug interactions</h3><!-- end field 55a71729-db51-49ef-b09d-a83f00fdfdf4 -->","summary":"","htmlStringContent":"<!-- begin item a5b7a0e5-5306-40dd-bb0b-a83f00fdf84a --><!-- begin field 95b275a7-0633-45f5-b3fc-a83f00fdfdf4 --><p>No interactions with crotamiton cream have been noted</p><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2017b</a>]</p><!-- end field 95b275a7-0633-45f5-b3fc-a83f00fdfdf4 --><!-- end item a5b7a0e5-5306-40dd-bb0b-a83f00fdf84a -->","subChapters":[]},{"id":"ec5848b9-336f-58ad-9366-475fe5f13e1f","slug":"dosing-information","fullItemName":"Dosing information","depth":3,"htmlHeader":"<!-- begin field aadfab63-799d-4570-89e4-a83d00027d42 --><h3>Dosing information</h3><!-- end field aadfab63-799d-4570-89e4-a83d00027d42 -->","summary":"","htmlStringContent":"<!-- begin item dc7e35af-dd56-482a-9937-a83d00027958 --><!-- begin field dfb3366a-fb17-4379-ab52-a83d00027d42 --><ul><li>The person should bathe in warm water and dry the skin well.</li><li>The cream should be rubbed into the entire body surface (excluding the face and scalp) until no traces remain visible.</li><li>The application should be repeated once daily, preferably in the evening, for a total of 3–5 days.</li><li>Depending on the response, special attention should be paid to sites that are particularly susceptible to infestation by the mites (eg interdigital spaces, wrists, axillae and genitalia).</li><li>Areas where there is pus formation should be covered with a dressing impregnated with the cream.</li><li>While the treatment is in progress the person may take a bath shortly before the next application.</li><li>After completion of the treatment, a cleansing bath should be taken followed by a change of bed linen and underclothing.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scabies/references/\">ABPI, 2017b</a>] </p><!-- end field dfb3366a-fb17-4379-ab52-a83d00027d42 --><!-- end item dc7e35af-dd56-482a-9937-a83d00027958 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}